Back to Journals » Biologics: Targets and Therapy » Volume 7

New and emerging treatments for ulcerative colitis: a focus on vedolizumab

Authors Gledhill T, Bodger K

Received 7 December 2012

Accepted for publication 18 January 2013

Published 23 May 2013 Volume 2013:7 Pages 123—130


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 5

Tamsin Gledhill,1 Keith Bodger2

1Digestive Diseases Centre, Aintree University Hospital Trust, 2Gastroenterology Department, Institute of Translational Medicine, University of Liverpool, Liverpool, UK

Abstract: Ulcerative colitis (UC) is the most common form of chronic inflammatory bowel disease and lacks a curative pharmacological treatment. Traditional therapies, which include 5-aminosalicylates, corticosteroids and immunosuppressants, aim to induce and maintain remission. Biological therapy with anti-tumor necrosis factor-alpha agents has added to the range of available treatments. Vedolizumab belongs to a new class of agents (integrin antagonists) that inhibit leukocyte adhesion and aim to selectively inhibit the inflammatory pathway. This article reviews the emerging data on the use of vedolizumab for UC. Evidence to date supports its efficacy in inducing remission in UC, with no major safety concerns identified.

Keywords: inflammatory bowel disease, effectiveness, integrin antagonists

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]